Science Researcher Update: Spotlight on Meetings, Conferences, and Events

 

Symposium - New York, United States

 

Phenotypic screening programs were the mainstay of target-based drug discovery and development until the 1980s. While over half of the compounds approved by the FDA between 1999 and 2008 were derived from phenotypic screening programs, recent challenges have shown the limitations of target- or pathway-based drug discovery, and this method of drug discovery struggles to gain acceptance. Many investigators are now revisiting the strategy of finding effective compounds using unbiased disease models, then using these effectors to identify a relevant drug target.

This symposium aims to deepen the level of scientific understanding behind phenotypic drug discovery and to foster the exchange of ideas between industry and academic research scientists. In this symposium, we will explore current strategies enabling phenotypic drug discovery to become more mainstream. We will discuss the ability of stem cell-based and -omics technologies to create highly relevant disease model systems in vitro. We will also discuss successful approaches to effectively identify specific targets to the effectors discovered using this strategy. Specific case studies will highlight notable successes in this approach.

Organization: New York Academy of Sciences

Phenotypic and Biomarker-Based Drug Discovery

 

If you'd like to ask a question or post a comment about this talk please do so below.